Wuhan Brightrun Pharmaceutical Technology Co., Ltd.
BRH
Company News
Tech Sharing
At the event's outset, the company proudly honored its top-performing employees of the quarter by presenting them with certificates of recognition and bespoke awards, celebrating their unwavering dedication to excellence in the biopharmaceutical testing field. Whether it was the technical experts who meticulously manage experimental data or the skilled managers who seamlessly coordinate projects, each individual exemplified the company’s core value of "Professionalism Drives Value" through their relentless pursuit of precision and innovation. Their exemplary efforts have become the benchmark for the entire team to strive toward. The room erupted in enthusiastic applause—both a heartfelt acknowledgment of these role models and a powerful testament to Berriheng employees' collective determination to continuously elevate themselves to meet the highest standards.
2025-05-30
In February 2025, Wuhan Buruiheng Pharmaceutical Technology Co., Ltd. officially became a member unit of the Wuhan East Lake National Independent Innovation Demonstration Zone Biomedical Industry Association, marking the company's deep integration into the innovation ecosystem of Optics Valley Bio-City and launching a new journey of collaborative industry-academia-research development.
2025-05-29
Recently, Wuhan Buruiheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Wuhan Buruiheng) successfully completed the on-site audit of its laboratory facilities and operational system conducted by an expert team from the Wuhan Municipal Health Commission, smoothly obtaining Level 2 Biosafety (BSL-2, also known as P2) laboratory registration under.Record number: E Health Safety BSL-2 [2023] 01-14-021
2023-10-08
On December 5, Wuhan Boreiheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Boreiheng") received the prestigious "Optics Valley Gazelle" Corporate Plaque for 2022, awarded by the Wuhan East Lake High-tech Development Zone. Recognized as a high-growth enterprise with strong technological capabilities, significant growth potential, and mastery of critical core technologies, Boreiheng has been proudly named among China's Optics Valley Gazelle companies.
2022-12-08
On May 8, 2025, the Hubei Provincial Department of Economy and Information Technology officially announced the seventh batch of provincial-level specialized, sophisticated, and innovative (SSM) SMEs. Wuhan Boreiheng Pharmaceutical Technology Co., Ltd. successfully earned the title of "Hubei Provincial SSM Enterprise," thanks to its strong advantages in specialization, precision, and distinctive development within the pharmaceutical technology sector—and after passing rigorous multi-level evaluations! This achievement marks another significant milestone for the company, following its recent recognition as a National High-Tech Enterprise, further solidifying its leadership in innovation capability, market competitiveness, and industry influence.
2022-05-09
On September 14, 2024, the third meeting of the Clinical Trial Contract Research Organization Branch (hereafter referred to as the CRO Branch) of the China Association for Pharmaceutical Quality Management was successfully held in Wuhan. Attendees included Ye Xiaoping, Chairman of Hangzhou Tigermed Co., Ltd. and Chairperson-elect of the CRO Branch; Wu Jie, Chairman of Northway (Beijing) Pharmaceutical Technology Co., Ltd.; along with nearly 60 representatives from 36 member organizations. The meeting was chaired by Wang Wei, Senior Vice President of Northway (Beijing) Pharmaceutical Technology Co., Ltd. and Secretary-General of the CRO Branch.
2021-11-12